GEMTUZUMAB OZOGAMICIN FOR RELAPSED OR PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA IN CHILDREN - EXPERIENCE OF THE POLISH PEDIATRIC LEUKEMIA AND LYMPHOMA STUDY GROUP (PPLLSG)

被引：0
|
作者：
Pawinska-Wasikowska, Katarzyna [1 ]
Bukowska-Strakova, Karolina [2 ]
Czogala, Malgorzata [1 ]
Wachowiak, Jacek [3 ]
Chaber, Radoslaw [4 ]
Szczepanski, Tomasz [5 ]
机构：
[1] Jagiellonian Univ Med Coll, Inst Pediat, Dept Pediat Oncol & Hematol, Krakow, Poland
[2] Jagiellonian Univ Med Coll, Inst Pediat, Dept Clin Immunol, Krakow, Poland
[3] Poznan Univ Med Sci, Dept Pediat Oncol Hematol & Transplantol, Poznan, Poland
[4] Univ Rzeszow, Inst Med Sci, Dept Pediat, Med Coll, Rzeszow, Poland
[5] Med Univ Silesia SUM, Dept Pediat Hematol & Oncol, Zabrze, Poland
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP269
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia
    Bayraktar, Ulas Darda
    Domingo, Gelenis Calzadilla
    Schmit, Jessica
    Pereira, Denise
    LEUKEMIA & LYMPHOMA, 2011, 52 (05) : 913 - 915
  • [12] Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia
    Chantepie, Sylvain P.
    Reboursiere, Emilie
    Mear, Jean-Baptiste
    Gac, Anne-Claire
    Salaun, Veronique
    Benabed, Khaled
    Cheze, Stephane
    Johnsonansah, Hyacinthe
    Macro, Margaret
    Vilque, Jean-Pierre
    Reman, Oumedaly
    LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2326 - 2330
  • [13] Gemtuzumab Ozogamicin In Refractory Childhood Acute Myeloid Leukemia
    Reinhardt, Dirk
    Zwaan, Christian M.
    Sander, Annette
    Neuhoff, Christine
    Kaspers, Gertjan J.
    Creutzig, Ursula
    BLOOD, 2010, 116 (21) : 470 - 470
  • [14] A phase II study of single-agent gemtuzumab ozogamicin in relapsed/refractory pediatric acute myeloid leukemia (AML).
    Zwaan, CM
    Reinhardt, D
    Zimmermann, M
    Creutzig, U
    Kaspers, GJL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 806S - 806S
  • [15] Gemtuzumab ozogamicin with FLAG-IDA is effective for children in relapsed/refractory acute myeloid leukemia.
    Cho, Bin
    Kim, Sun Young
    Lee, Dae Hyoung
    Kwon, Young Joo
    Park, Young Shil
    Hwang, Hui Sung
    Park, Ji Kyoung
    Jang, Pil Sang
    Chung, Nak Gyun
    Jeong, Dae-Chul
    Kim, Hack Ki
    BLOOD, 2006, 108 (11) : 218B - 218B
  • [16] Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia
    Bross, PF
    Beitz, J
    Chen, G
    Chen, XH
    Duffy, E
    Kieffer, L
    Roy, S
    Sridhara, R
    Rahman, A
    Williams, G
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2001, 7 (06) : 1490 - 1496
  • [17] Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia
    Buckwalter, M
    Dowell, JA
    Korth-Bradley, J
    Gorovits, B
    Mayer, PR
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 873 - 880
  • [18] High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
    Stone, Richard M.
    Moser, Barry
    Sanford, Ben
    Schulman, Philip
    Kolitz, Jonathan E.
    Allen, Steven
    Stock, Wendy
    Galinsky, Ilene
    Vij, Ravi
    Marcucci, Guido
    Hurd, David
    Larson, Richard A.
    LEUKEMIA RESEARCH, 2011, 35 (03) : 329 - 333
  • [19] Gemtuzumab ozogamicin in acute myeloid leukemia
    Godwin, C. D.
    Gale, R. P.
    Walter, R. B.
    LEUKEMIA, 2017, 31 (09) : 1855 - 1868
  • [20] Gemtuzumab ozogamicin for acute myeloid leukemia
    Appelbaum, Frederick R.
    Bernstein, Irwin D.
    BLOOD, 2017, 130 (22) : 2373 - 2376
12345